Category Archives: Prevention

Integration models for delivering COVID-19 vaccines through HIV services in low-and middle-income countries: A scoping review

2025

BACKGROUND: The Coronavirus Disease 2019 (COVID-19) remains a major global public health issue. People living with HIV (PLHIV) are among the vulnerable groups facing a higher risk of severe outcomes....

HIV pre-exposure prophylaxis among people with criminal justice involvement in the United States: A systematic review

2025

People with criminal justice involvement (PCJI) face a heightened risk of HIV yet remain underserved by prevention strategies such as pre-exposure prophylaxis (PrEP). This systematic review synthesizes current evidence on...

Human milk oligosaccharides, microbiome, antiretroviral therapy and HIV infected mothers: Reasons to still promote breastfeeding in HIV context of lactating countries, a mini-narrative review

2025

Breastfeeding is the preferred feeding for newborns during the first 6 months of life and until the age of 2 years or beyond. The benefits of breastfeeding remain significant, even in cases...

Integrating PrEP and sexual reproductive health services for adolescent girls and young women in South Africa: A scoping review

2025

Adolescent girls and young women (AGYW) in South Africa bear a disproportionate burden of the global HIV epidemic. Integrating PrEP into sexual and reproductive health (SRH) services offers a promising...

Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: A systematic review and meta-analysis

2025

Background Diagnosing human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections in general population settings is challenging. We conducted a systematic review and meta-analysis of...

An integrative review of PrEP promotion strategies at historically Black colleges and universities to reduce HIV disparities

2025

PURPOSE OF REVIEW: We searched PubMed, CINAHL Plus, Embase, Scopus, Web of Science, and ERIC to identify peer-reviewed studies published between 2015 and 2025 that discussed PrEP at HBCUs. We...

The association between different levels of suppressed viral load and the risk of sexual transmission of HIV among serodiscordant couples on antiretroviral therapy: A systematic review

2025

The risk of sexual transmission of HIV in serodiscordant couples when the partner living with HIV (PLHIV) uses antiretroviral therapy (ART) and maintains a suppressed viral load (VL) (< 200...

Contextual and culturally adapted interventions to improve HIV outcomes: A scoping review

2025

BACKGROUND: Antiretroviral therapy is widely available, yet structural, social, and cultural barriers still limit human immunodeficiency virus prevention and care. Prevention tools such as consistent condom use and pre-exposure prophylaxis...

Influences of gender-based stigma on HIV prevention and care among older women: A scoping review

2025

Older women living with HIV are uniquely situated at multiple marginalized intersections because of their gender, age, and HIV status. However, research into how gender-based stigma (GBS) affects HIV prevention...

Investigating the influence of provider communication and language reframing on HIV pre-exposure prophylaxis (PrEP) engagement with Black African and Caribbean women: A systematic review

2025

Patient-provider engagement with HIV pre-exposure prophylaxis (PrEP) continues to exhibit significant disparities, particularly among Black African and Caribbean (BAC) women. In the United Kingdom, cisgender women accounted for one-third of...

The safety of cabotegravir in pregnancy: A systematic review and meta-analysis

2025

BACKGROUND: HIV remains an important global public health crisis. Antiretroviral treatment has been essential to suppress viral replication, and in at-risk individuals, antiretroviral pre-exposure prophylaxis drugs (PrEP) lower transmission rates....

Efficacy of raltegravir in achieving virological suppression at delivery in HIV-positive pregnant women: A systematic review and meta-analysis

2025

Background The world’s first HIV integrase inhibitor, raltegravir (RAL), has been widely used for the treatment of HIV infection over the past 15 years, and continues benefiting people living with...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!